Financially, UroGen has a market cap of $464mn and a cash runway of 8-9 quarters, despite facing patent challenges from Teva.

Using multiparametric MRI in place of TURBT in the initial staging of new bladder cancers can expedite treatment of muscle-invasive bladder cancer.

Incorporating multiparametric magnetic resonance imaging (mpMRI) for initial staging can reduce the time to correct treatment (TTCT) for patients with muscle-invasive bladder cancer (MIBC), according ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

The most common symptom is blood in the urine (hematuria), which may appear pink, red, or brown. Other signs include frequent ...

“Incorporating mpMRI ahead of TURBT into the standard pathway was beneficial for all patients with suspected [muscle invasive bladder cancer],” the authors of the new study wrote. “TURBT ...

Data from the phase 3 ENVISION trial demonstrate the potential of UGN-102 as an effective and durable nonsurgical treatment ...

The study saw 143 patients with suspected bladder cancer randomized into two groups, either going through the usual test called transurethral resection of bladder tumor (TURBT), or an initial MRI ...

The BladderPath trial looked at whether adding in some extra or alternative diagnostic testing, mpMRI first then and biopsy or TURBT, could speed up the time taken to receive the correct treatment ...

The study, funded by the UK National Institute for Health and Care Research, saw 143 patients with suspected bladder cancer randomised into two groups, either going through the usual test called ...

The median time to correct treatment was 98 days with initial TURBT vs 53 days with initial mpMRI. Adding multiparametric magnetic resonance imaging (mpMRI) into the initial staging pathway for muscle ...